source
- Tandem Diabetes Care gets FDA clearance for tubeless insulin delivery system with up to 7-day wearTandem Diabetes Care announced that the FDA has cleared its Tandem Mobi system as a tubeless automated insulin delivery device. The clearance allows the device to be worn for up to seven days witho…
- Industry groups push for clearer FDA guidance on ANDA and 505(b)(2) filings amid rising patent thicketsIndustry trade groups representing brand‑name and generic manufacturers have asked the FDA to clarify its recent guidance on when a company should file an abbreviated new drug application (ANDA) ve…